Purple Biotech Ltd - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
PPBT Nasdaq 2830 purple-biotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Purple Biotech Ltd

Top Midday Gainers - Sep 2nd, 2026 11:50 am
Purple Biotech U.S. Patent Allowance Strengthens CAPTN-3 Multispecific Antibody Protection - Sep 2nd, 2026 9:07 am
New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies - Sep 2nd, 2026 5:30 am
Purple Biotech Reports Second Quarter 2026 Financial Results - Aug 7th, 2026 5:00 am
Purple Biotech Presents New IM1240 Preclinical Data Showing Anti-Tumor Activity and Broad Therapeutic Window (PPBT) - Jun 11th, 2026 8:38 am
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window - Jun 11th, 2026 5:00 am
Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights - May 15th, 2026 5:00 am
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240 - Apr 27th, 2026 5:00 am
Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform - Apr 23rd, 2026 5:00 am
Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240 - Jan 7th, 2026 6:00 am
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform - Oct 29th, 2025 5:33 am